Skip to main content
Drugs.com - Go to homepage
Browse all medications:
  • a
  • b
  • c
  • d
  • e
  • f
  • g
  • h
  • i
  • j
  • k
  • l
  • m
  • n
  • o
  • p
  • q
  • r
  • s
  • t
  • u
  • v
  • w
  • x
  • y
  • z
  • 0-9
Advanced Search
Register Sign In
  • Account
    • Sign in
    • Create an account
  • Drugs A-Z
  • Pill Identifier
  • Drug Interaction Checker
  • Compare Drugs
  • News
  • Pro Edition
  • More Resources
  • Help & Support
  1. Home
  2. News
  3. Clinical Trials
  • All News
  • Consumer
  • Pro
  • New Drugs
  • Pipeline
  • Clinical Trials
  • FDA Alerts

Low-Dose Atropine Eyedrops No Better Than Placebo for Slowing Myopia Progression

July 13, 2023 -- Use of low-dose atropine eyedrops (concentration 0.01%) was no better than placebo at slowing myopia (nearsightedness) progression and elongation of the eye among children treated for two years, according to a randomized controlled trial conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and funded by the National Eye Institute (NEI). The trial aimed to identify an effective way to manage this leading and increasingly common cause of refractive error, which can cause serious uncorrectable vision loss later in life. Results from the trial were published in JAMA Ophthalmology.

Importantly, the findings contradict results from recent trials, primarily in East Asia, which showed a benefit from 0.01% atropine in slowing myopia.

“The overall mixed results on low-dose atropine show us we need more research. Would a different dose be more effective in a US population? Would combining atropine with other strategies have a synergistic effect? Could we develop other approaches to treatment or prevention based on a better understanding of what causes myopia progression?” said Michael F. Chiang, M.D., director of the NEI, which is part of the National Institutes of Health.

Identifying an optimal approach for preventing high (advanced) myopia is urgently needed given the escalating prevalence of myopia overall and the risk of it progressing to high myopia. By 2030, it’s predicted that 39 million people in the U.S. will have myopia. By 2050, that number is expected to grow to 44 million in the U.S. and to 50% of the global population.

Much stronger concentrations of atropine eyedrops (0.5-1.0%) have long been used by pediatric eye doctors to slow myopia progression. While effective, such doses cause light sensitivity and blurry near vision while on the nightly eyedrops. Thus, there is interest in clinical studies assessing lower concentrations that have been shown to have fewer side effects.

“The absence of a treatment benefit in our U.S.-based study, compared with East Asian studies, may reflect racial differences in atropine response. The study enrolled fewer Asian children, whose myopia progresses more quickly, and included Black children, whose myopia progresses less quickly compared with other races,” noted the study’s lead co-author, Michael X. Repka, M.D., professor of ophthalmology, Johns Hopkins University.

For the study, 187 children ages 5 to 12 years with low-to-moderate bilateral myopia were randomly assigned to use nightly atropine (0.01%) (125 children) or placebo (62 children) eyedrops for two years. Study participants, their parents, and the eye care providers were masked to the group assignments. Patient care was provided at 12 study center sites throughout the U.S.

After the treatment period, and 6 months after treatment stopped, there were no significant differences between the groups in terms of changes in degree of myopia compared with baseline. Nor were there significant differences in axial length within the two groups when compared with baseline measurements.

“It's possible that a different concentration of atropine is needed for U.S. children to experience a benefit,” noted the study’s other lead co-author, Katherine K. Weise, O.D., professor, University of Alabama at Birmingham. “Clinical researchers could evaluate new pharmaceuticals and special wavelengths of light in combination with optical strategies, like special glasses or contact lenses, to see what works in reducing the progression of myopia.”

Among children, myopia will stabilize in about half of children around age 16 years, and among an increasingly larger percentage as they get older. By their early twenties, about 10% of individuals with myopia will continue to grow more nearsighted, and by age 24 years that percentage is 4%.

“Vision scientists may help us figure out what’s different about the myopic eye, even among different races and ethnicities, to help create new treatment strategies,” she said. It will take a real convergence of eye research to solve the environmental, genetic, and structural mystery of myopia.”

PEDIG is a collaborative network of pediatric ophthalmologists and pediatric optometrists dedicated to conducting multi-center trials on eye disorders that affect children. The trial was funded by the NEI grants EY11751, EY18810 and EY23198. The ClinicalTrials.gov identifier is NCT03334253.

For more information about myopia, visit https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/nearsightedness-myopia.

NEI leads the federal government’s efforts to eliminate vision loss and improve quality of life through vision research…driving innovation, fostering collaboration, expanding the vision workforce, and educating the public and key stakeholders. NEI supports basic and clinical science programs to develop sight-saving treatments and to broaden opportunities for people with vision impairment. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®

References

Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, Kehler LAF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA, on behalf of the Pediatric Eye Disease Investigator Group. “Randomized trial of low-dose atropine eyedrops for myopia control”, published July 13, 2023 in JAMA Ophthalmology.

Source: NIH

Posted: July 2023

More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Clinical Trial Results
  • Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Recently Approved
  • Tryptyr

    Tryptyr (acoltremon) is a first-in-class TRPM8 thermoreceptor agonist indicated...

  • Yutrepia

    Yutrepia (treprostinil) is an inhaled dry powder formulation of the...

  • Starjemza

    Starjemza (ustekinumab-hmny) is a human interleukin-12 and -23 antagonist...

More drug approvals

Subscribe to our newsletters
Select one or more newsletters to continue.
Stay up-to-date
  • Subscribe to RSS feeds
  • Subscribe to email
Drugs.com Mobile App

Access drug & treatment information, identify pills, check interactions and set up personal medication records.

Download the Medication Guide app on iTunes Download the Medication Guide app on the Google Play store
Drugs.com mobile app
Drugs.com
About
  • About Drugs.com
  • Advertising policy
  • Attribution & citations
Terms & privacy
  • Terms of use
  • Editorial policy
  • Privacy policy
Support
  • Help center
  • Sitemap
  • Contact us
  • Subscribe to Drugs.com newsletters
  • Follow Drugs.com on Facebook
  • Follow Drugs.com on Twitter
  • Follow Drugs.com on Instagram
  • Follow Drugs.com on YouTube
  • Follow Drugs.com on Pinterest

Subscribe to our newsletter for the latest medication news, new drug approvals and FDA alerts.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex (updated 4 May 2025), Cerner Multum™ (updated 25 May 2025), ASHP (updated 11 May 2025) and others.
Certified by TRUSTe Verified by TAG This website is certified by AACI. Click to verify. AdChoices - Ad privacy information
Copyright © 2000-2025 Drugs.com. All rights reserved.